1-acetyl-2,6-dimethylbenzene-4-carbonitrile | 118738-93-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-acetyl-2,6-dimethylbenzene-4-carbonitrile
• 英文别名: 4-acetyl-3,5-dimethyl-benzonitrile；4-Acetyl 3,5-dimethyl benzonitrile；4-acetyl-3,5-dimethylbenzonitrile
• CAS: 118738-93-5
• 化学式: C₁₁H₁₁NO
• 分子量: 173.214
• InChiKey: HZQUAMCVQNXYTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-acetyl-2,6-dimethylbenzene-4-carbonitrile 在 sodium hydroxide 作用下， 以81%的产率得到1-acetyl-2,6-dimethylbenzene-4-carboxylic acid
  参考文献：
  名称：

  Al-Ka'bi, Ja'far; Farooqi, Jameel A.; Gore, Peter H., Journal of the Chemical Society. Perkin transactions II, 1988, p. 943 - 950

  摘要：

  DOI：
• 作为产物：
  描述：

  4-bromo-2,6-dimethylacetophenone 、 copper(l) cyanide 在 copper(l) iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以38%的产率得到1-acetyl-2,6-dimethylbenzene-4-carbonitrile
  参考文献：
  名称：

  New 1,2,4-triazine derivatives and biological applications thereof

  摘要：

  这项发明涉及公式(I)的新1,2,4-三嗪衍生物： 其中A、B、R2和Y在申请中有定义， 它们的制备和中间体，它们作为药物和药物组合物的用途以及含有它们的关联物。 公式(I)的化合物能够抑制细菌七糖合成。

  公开号：

  EP2141164A1

文献信息

• Heterocyclic derivatives, process for their preparation and their
  申请人：Sanofi

  公开号：US05780468A1

  公开（公告）日：1998-07-14

  The invention relates to compounds of formula: ##STR1## in which: A is selected from O or S; B is selected from C or N; Z.sub.1 is selected from C.sub.1 -C.sub.4 alkylene or phenylene; Z.sub.2 is C.sub.1 -C.sub.4 alkylene; W is NR.sub.1 R.sub.2, in which R.sub.1 is selected from H or C.sub.1 -C.sub.4 alkyl and R.sub.2 is selected from H, C.sub.1 -C.sub.4 alkyl, CONQ.sub.1 Q.sub.2 or CSNQ.sub.1 Q.sub.2 in which Q.sub.1 and Q.sub.2 are independently selected from H or C.sub.1 -C.sub.4 alkyl, SO.sub.2 Q.sub.3 or COQ.sub.3 in which Q.sub.3 is C.sub.1 -C.sub.4 alkyl, COOQ.sub.4 in which Q.sub.4 is selected from C.sub.1 -C.sub.4 alkyl or benzyl, or R.sub.1 and R.sub.2 taken together with N form a saturated heterocycle, or W is selected from C.sub.1 -C.sub.4 alkoxy or thioalkoxy, CONQ.sub.1 Q.sub.2 or CSNQ.sub.1 Q.sub.2, pyridyl, imidazolyl or COOQ.sub.5 in which Q.sub.5 is C.sub.1 -C.sub.5 alkyl; R.sub.3 is not present when B is N, or is H, C.sub.1 -C.sub.8 alkyl or halogen; Ar.sub.1 is selected from optionally substituted phenyl, thienyl, furyl, indolyl, naphthyl or benzyl or Ar.sub.1 and R.sub.3 taken together form a phenylalkylene group; Ar.sub.2 is selected from pyrimidinyl, quinolyl, isoquinolyl, indolyl, isoindolyl or pyridyl, optionally substituted; as well as their salts. Use as medicines.

  本发明涉及式子的化合物：##STR1## 其中：A选自O或S; B选自C或N; Z.sub.1选自C.sub.1-C.sub.4烷基或苯基; Z.sub.2选自C.sub.1-C.sub.4烷基; W为NR.sub.1R.sub.2，其中R.sub.1选自H或C.sub.1-C.sub.4烷基，R.sub.2选自H，C.sub.1-C.sub.4烷基，CONQ.sub.1Q.sub.2或CSNQ.sub.1Q.sub.2，其中Q.sub.1和Q.sub.2独立选自H或C.sub.1-C.sub.4烷基，SO.sub.2Q.sub.3或COQ.sub.3，其中Q.sub.3为C.sub.1-C.sub.4烷基，COOQ.sub.4，其中Q.sub.4选自C.sub.1-C.sub.4烷基或苄基，或R.sub.1和R.sub.2与N结合形成饱和杂环，或W选自C.sub.1-C.sub.4烷氧基或硫代烷氧基，CONQ.sub.1Q.sub.2或CSNQ.sub.1Q.sub.2，吡啶基，咪唑基或COOQ.sub.5，其中Q.sub.5选自C.sub.1-C.sub.5烷基; 当B为N时，R.sub.3不存在，否则为H，C.sub.1-C.sub.8烷基或卤素; Ar.sub.1选自可选取代的苯基，噻吩基，呋喃基，吲哚基，萘基或苄基，或Ar.sub.1和R.sub.3结合形成苯基烷基基团; Ar.sub.2选自嘧啶基，喹啉基，异喹啉基，吲哚基，异吲哚基或吡啶基，可选取代; 以及它们的盐。用作药物。
• Novel HldE-K Inhibitors Leading to Attenuated Gram Negative Bacterial Virulence
  作者：Nicolas Desroy、Alexis Denis、Chrystelle Oliveira、Dmytro Atamanyuk、Sophia Briet、Fabien Faivre、Géraldine LeFralliec、Yannick Bonvin、Mayalen Oxoby、Sonia Escaich、Stéphanie Floquet、Elodie Drocourt、Vanida Vongsouthi、Lionel Durant、François Moreau、Theodore B. Verhey、Ting-Wai Lee、Murray S. Junop、Vincent Gerusz

  DOI：10.1021/jm301499r

  日期：2013.2.28

  We report here the optimization of an HldE kinase inhibitor to low nanomolar potency, which resulted in the identification of the first reported compounds active on selected E. coli strains. One of the most interesting candidates, compound 86, was shown to inhibit specifically bacterial I,PS heptosylation on efflux pump deleted E. coli strains. This compound did not interfere with E. coli bacterial growth (MIC > 32 mu g/mL) but sensitized this pathogen to hydrophobic antibiotics like macrolides normally inactive on Gram-negative bacteria. In addition, 86 could sensitize E. coli to serum complement killing. These results demonstrate that HldE kinase is a suitable target for drug discovery. They also pave the way toward novel possibilities of treating or preventing bloodstream infections caused by pathogenic Gram negative bacteria by inhibiting specific virulence factors.
• US5470855A
  申请人：——

  公开号：US5470855A

  公开（公告）日：1995-11-28
• US5780468A
  申请人：——

  公开号：US5780468A

  公开（公告）日：1998-07-14
• US5891893A
  申请人：——

  公开号：US5891893A

  公开（公告）日：1999-04-06